195 related articles for article (PubMed ID: 25066124)
1. Complement-dependent modulation of antitumor immunity following radiation therapy.
Elvington M; Scheiber M; Yang X; Lyons K; Jacqmin D; Wadsworth C; Marshall D; Vanek K; Tomlinson S
Cell Rep; 2014 Aug; 8(3):818-30. PubMed ID: 25066124
[TBL] [Abstract][Full Text] [Related]
2. Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy.
Zhu P; Bailey SR; Lei B; Paulos CM; Atkinson C; Tomlinson S
Transplantation; 2017 Apr; 101(4):e75-e85. PubMed ID: 28045880
[TBL] [Abstract][Full Text] [Related]
3. A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer.
Elvington M; Huang Y; Morgan BP; Qiao F; van Rooijen N; Atkinson C; Tomlinson S
Blood; 2012 Jun; 119(25):6043-51. PubMed ID: 22442351
[TBL] [Abstract][Full Text] [Related]
4. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.
Sekine H; Kinser TT; Qiao F; Martinez E; Paulling E; Ruiz P; Gilkeson GS; Tomlinson S
Arthritis Rheum; 2011 Apr; 63(4):1076-85. PubMed ID: 21452327
[TBL] [Abstract][Full Text] [Related]
5. Complement Inhibition: A Novel Form of Immunotherapy for Colon Cancer.
Downs-Canner S; Magge D; Ravindranathan R; O'Malley ME; Francis L; Liu Z; Sheng Guo Z; Obermajer N; Bartlett DL
Ann Surg Oncol; 2016 Feb; 23(2):655-62. PubMed ID: 26289805
[TBL] [Abstract][Full Text] [Related]
6. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection.
Atkinson C; Song H; Lu B; Qiao F; Burns TA; Holers VM; Tsokos GC; Tomlinson S
J Clin Invest; 2005 Sep; 115(9):2444-53. PubMed ID: 16127466
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration.
Lavergne E; Combadière C; Iga M; Boissonnas A; Bonduelle O; Maho M; Debré P; Combadiere B
J Immunol; 2004 Sep; 173(6):3755-62. PubMed ID: 15356122
[TBL] [Abstract][Full Text] [Related]
8. Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression.
Wang Y; Sun SN; Liu Q; Yu YY; Guo J; Wang K; Xing BC; Zheng QF; Campa MJ; Patz EF; Li SY; He YW
Cancer Discov; 2016 Sep; 6(9):1022-35. PubMed ID: 27297552
[TBL] [Abstract][Full Text] [Related]
9. Fusion of C3d with hemagglutinin enhances protective immunity against swine influenza virus.
Li GX; Tian ZJ; Yu H; Jin YY; Hou SH; Zhou YJ; Liu TQ; Hu SP; Tong GZ
Res Vet Sci; 2009 Jun; 86(3):406-13. PubMed ID: 19010505
[TBL] [Abstract][Full Text] [Related]
10. Regulation of the alternative pathway of complement modulates injury and immunity in a chronic model of dextran sulphate sodium-induced colitis.
Elvington M; Schepp-Berglind J; Tomlinson S
Clin Exp Immunol; 2015 Mar; 179(3):500-8. PubMed ID: 25293413
[TBL] [Abstract][Full Text] [Related]
11. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.
Michelfelder S; Fischer F; Wäldin A; Hörle KV; Pohl M; Parsons J; Reski R; Decker EL; Zipfel PF; Skerka C; Häffner K
J Am Soc Nephrol; 2018 Apr; 29(4):1141-1153. PubMed ID: 29335241
[TBL] [Abstract][Full Text] [Related]
12. The complement system contributes to the pathology of experimental autoimmune encephalomyelitis by triggering demyelination and modifying the antigen-specific T and B cell response.
Hundgeburth LC; Wunsch M; Rovituso D; Recks MS; Addicks K; Lehmann PV; Kuerten S
Clin Immunol; 2013 Mar; 146(3):155-64. PubMed ID: 23352967
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression.
Urquiza M; Melo-Cardenas J; Aguillon R; Kipps TJ; Castro JE
Hum Gene Ther; 2015 Jan; 26(1):14-25. PubMed ID: 25382101
[TBL] [Abstract][Full Text] [Related]
14. Salidroside Restores an Anti-inflammatory Endothelial Phenotype by Selectively Inhibiting Endothelial Complement After Oxidative Stress.
Wang Y; Su Y; Lai W; Huang X; Chu K; Brown J; Hong G
Inflammation; 2020 Feb; 43(1):310-325. PubMed ID: 31701353
[TBL] [Abstract][Full Text] [Related]
15. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
16. Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity.
Qin H; Cha SC; Neelapu SS; Lou Y; Wei J; Liu YJ; Kwak LW
Blood; 2009 Nov; 114(19):4142-9. PubMed ID: 19749091
[TBL] [Abstract][Full Text] [Related]
17. Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8
Qiao J; Liu Z; Dong C; Luan Y; Zhang A; Moore C; Fu K; Peng J; Wang Y; Ren Z; Han C; Xu T; Fu YX
Cancer Cell; 2019 Jun; 35(6):901-915.e4. PubMed ID: 31185213
[TBL] [Abstract][Full Text] [Related]
18. Complement Activation via a C3a Receptor Pathway Alters CD4
Kwak JW; Laskowski J; Li HY; McSharry MV; Sippel TR; Bullock BL; Johnson AM; Poczobutt JM; Neuwelt AJ; Malkoski SP; Weiser-Evans MC; Lambris JD; Clambey ET; Thurman JM; Nemenoff RA
Cancer Res; 2018 Jan; 78(1):143-156. PubMed ID: 29118090
[TBL] [Abstract][Full Text] [Related]
19. Induction of protective and therapeutic antitumor immunity by a DNA vaccine with C3d as a molecular adjuvant.
Xu GL; Zhang KQ; Guo B; Zhao TT; Yang F; Jiang M; Wang QH; Shang YH; Wu YZ
Vaccine; 2010 Oct; 28(44):7221-7. PubMed ID: 20800113
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal stem cells are injured by complement after their contact with serum.
Li Y; Lin F
Blood; 2012 Oct; 120(17):3436-43. PubMed ID: 22966167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
